New Obesity Drug Cagrisema Outperforms Zepbound in Clinical Trials
News Desk
COPENHAGEN: Danish pharmaceutical giant Novo Nordisk has achieved a major breakthrough in weight management research as its experimental drug, Cagrisema, outperformed Eli Lilly's widely popular Zepbound in recent clinical trials.…